Ketoconazole shampoo in the treatment of seborrhoeic dermatitis in patients with HIV infection.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Ketoconazole shampoo in the treatment of seborrhoeic dermatitis in patients with HIV infection.

Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:261 (unnumbered poster). Unique Identifier : AIDSLINE ASHM6/95291837
Duncombe C; Bloch M; Quan D; Holdsworth House General Practice, Darlinghurst NSW.

Abstract: STUDY OBJECTIVES: To assess the safety and efficacy of Ketoconazole applied as a 2% shampoo in the treatment of seborrhoeic dermatitis in patients with concomitant HIV infection. METHODOLOGY: 46 HIV positive patients with moderate to severe facial and scalp seb. derm. applied Ketoconazole as a 2% shampoo to the scalp massaging the lather over the face and other affected areas leaving contact with the skin for five minutes. Treatment was for three consecutive days then twice weekly for four weeks. SUMMARY OF RESULTS: 31 patients reported complete resolution of scaling, erythema and itch. 13 patients reported a marked improvement in symptoms. Two patients reported a moderate improvement. There were no adverse events reported and all participants completed the four week course of treatment. CONCLUSION: Seborrhoeic dermatitis is a common condition in people with HIV infection. There appears to be a causative relationship between the yeast Pityrosporum and seborrhoeic dermatitis, hence the rationale for using the topical anti-fungal agent Ketoconazole. The shampoo as a delivery agent is 'patient-friendly' and compliance was good. Ketoconazole shampoo is an effective and safe treatment for seborrhoeic dermatitis. Immunosuppressed patients often will need maintenance therapy.

Keywords: Administration, Topical AIDS-Related Opportunistic Infections/*DRUG THERAPY Dermatitis, Seborrheic/*DRUG THERAPY *Hair Preparations Human Ketoconazole/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS ABSTRACT
950930
M9591125

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .